STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer

Biomolecules. 2022 Oct 9;12(10):1450. doi: 10.3390/biom12101450.

Abstract

The signal transducer and activator of transcription (STAT) is a family of intracellular cytoplasmic transcription factors involved in many biological functions in mammalian signal transduction. Among them, STAT3 is involved in cell proliferation, differentiation, apoptosis, and inflammatory responses. Despite the advances in the treatment of pancreatic cancer in the past decade, the prognosis for patients with pancreatic cancer remains poor. STAT3 has been shown to play a pro-cancer role in a variety of cancers, and inhibitors of STAT3 are used in pre-clinical and clinical studies. We reviewed the relationship between STAT3 and pancreatic cancer and the latest results on the use of STAT3 inhibitors in pancreatic cancer, with the aim of providing insights and ideas around STAT3 inhibitors for a new generation of chemotherapeutic modalities for pancreatic cancer.

Keywords: STAT3; drug therapy; molecular targeted therapy; pancreatic cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Cell Line, Tumor
  • Humans
  • Mammals / metabolism
  • Pancreatic Neoplasms* / drug therapy
  • STAT3 Transcription Factor* / metabolism
  • Signal Transduction / physiology

Substances

  • STAT3 Transcription Factor
  • STAT3 protein, human

Grants and funding

This work is supported by National Natural Science Foundation of China (82260555); the Gansu Traditional Chinese Medicine Research Project (GZKP-2020-28); Natural Science Foundation of Gansu Province (2020-0405-JCC-1871) and Lanzhou City Chengguan District Science and Technology Plan Project (2020-2-11-4).